SCHEMBL26554263

SCHEMBL26554263

CC(C)(C)OC(=O)NCCNc1nc2cc(Br)ccc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.46
HDAC6 Q9UBN7 1/20 0.42
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
HIF1A Q16665 1/20 0.41
LATS1 O95835 1/20 0.41
SUV39H2 Q9H5I1 2/20 0.40
FBP1 P09467 1/20 0.40
BRD4 O60885 1/20 0.40
MALT1 Q9UDY8 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26554279 0.94 STK17B (0.44) BCHEHDAC6KDM4EMAPTALDH1A1
SCHEMBL29437012 0.94 USP2 (0.43) HDAC6BRD4USP2LMNA
SCHEMBL29437026 0.94 STK17B (0.44) BCHEHDAC6KDM4EMAPTALDH1A1
SCHEMBL26554281 0.94 USP2 (0.43) HDAC6BRD4USP2LMNA
SCHEMBL29437062 0.93 USP2 (0.44) KDM4EMAPTBRD4NPC1RAB9A
SCHEMBL26554287 0.93 USP2 (0.44) KDM4EMAPTBRD4NPC1RAB9A
SCHEMBL26554307 0.91 BCHE (0.46) BCHEKDM4EMAPTALDH1A1GLA
SCHEMBL17830181 0.87 ANO1 (0.47) BCHEKDM4EMAPTALDH1A1GLA
SCHEMBL23336053 0.85 BCHE (0.44) BCHEHDAC6KDM4EMAPTALDH1A1
SCHEMBL26554310 0.85 STK17B (0.44) BCHEKDM4EMAPTALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
EP-4211111-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2023-07-19 EP disclosed
WO-2022056045-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 BCHE 1326/4885HDAC6 558/4885KDM4E 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.